

Application No.  
Amendment Dated  
Page 6 of 7

10/550,038  
08/23/2006

**Remarks/Arguments:**

Claims 1, 2, 4, 6, 8, and 11 to 13 are pending in the instant application. By this amendment, Applicants have amended claim 1, and have cancelled claims 2 and 12. No new matter has been added by the amendment to claim 1.

**Election/Restriction**

On August 15, 2006, the Examiner discussed the instant application in a telephone conversation with Applicants' undersigned representative. The Examiner indicated that he was issuing a further restriction requirement. In particular, the Examiner stated that the definition of Q in claim should be directed to only of Q1 or Q2, as each is independent and distinct from the other. Additionally, the Examiner stated that method claim 12 should be withdrawn as it is allegedly directed to an invention independent and distinct from the invention recited in the claims 1, 2, 4, 6, 8, 11, and 13.

In order to expedite prosecution of the instant application, Applicants have herein elected Q1 as the definition for Q. Additionally, Applicants have cancelled method claim 12.

**Obviousness-Type Double Patenting**

The Examiner rejected the present claims over those of copending U.S. Application No. 10/550,039. The Examiner stated that he has found the claims of the '039 Application to be allowable.

In order to expedite prosecution of the instant application, Applicants herewith submit a terminal disclaimer, disclaiming the terminal part of the statutory term of any patent granted on this application beyond the expiration of any patent which issues from U.S. Application No. 10/550,039.


Applicants believe the application is now in condition for allowance, which action is respectfully requested.

Application No.  
Amendment Dated  
Page 7 of 7

10/550,038  
08/23/2006

Although Applicants believe no additional fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 100869-1P US.

Respectfully submitted,

  
Name: John X. Haberman  
Dated: August 23, 2006  
Reg. No.: 55,236  
Phone No.: 781-839-4736  
Global Intellectual Property, Patents  
AstraZeneca R&D Boston  
35 Gatehouse Drive  
Waltham, MA 02451